Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Jennifer Nelson writes about all things money--personal finance, investing, saving, credit cards and insurance for numerous publications including AARP, Next Avenue, Credit Karma, Real SImple, Citi ...

If you haven't been paying attention, the narrative that the Knicks can't play defense has been taking quite the hit recently. New York owns the league's best defense, by an appreciable margin, over ...